DE602007012677D1 - Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen - Google Patents

Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen

Info

Publication number
DE602007012677D1
DE602007012677D1 DE602007012677T DE602007012677T DE602007012677D1 DE 602007012677 D1 DE602007012677 D1 DE 602007012677D1 DE 602007012677 T DE602007012677 T DE 602007012677T DE 602007012677 T DE602007012677 T DE 602007012677T DE 602007012677 D1 DE602007012677 D1 DE 602007012677D1
Authority
DE
Germany
Prior art keywords
compounds
problementation
iamine
pyrimidine
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007012677T
Other languages
German (de)
English (en)
Inventor
Esteban Masuda
Donald G Payan
Elliott B Grossbard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigel Pharmaceuticals Inc
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of DE602007012677D1 publication Critical patent/DE602007012677D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE602007012677T 2006-04-18 2007-03-21 Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen Active DE602007012677D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/407,233 US8227455B2 (en) 2005-04-18 2006-04-18 Methods of treating cell proliferative disorders
PCT/US2007/064511 WO2007124221A1 (en) 2006-04-18 2007-03-21 Methods of treating cell proliferative disorders by using pyrimidinediamine compounds

Publications (1)

Publication Number Publication Date
DE602007012677D1 true DE602007012677D1 (de) 2011-04-07

Family

ID=38477280

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007012677T Active DE602007012677D1 (de) 2006-04-18 2007-03-21 Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen

Country Status (10)

Country Link
US (2) US8227455B2 (cg-RX-API-DMAC7.html)
EP (1) EP2010181B1 (cg-RX-API-DMAC7.html)
JP (1) JP5204761B2 (cg-RX-API-DMAC7.html)
AT (1) ATE499102T1 (cg-RX-API-DMAC7.html)
CA (1) CA2649549C (cg-RX-API-DMAC7.html)
DE (1) DE602007012677D1 (cg-RX-API-DMAC7.html)
DK (1) DK2010181T3 (cg-RX-API-DMAC7.html)
ES (1) ES2364657T3 (cg-RX-API-DMAC7.html)
SI (1) SI2010181T1 (cg-RX-API-DMAC7.html)
WO (1) WO2007124221A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1663242T3 (da) * 2003-08-07 2011-08-01 Rigel Pharmaceuticals Inc 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
US8227455B2 (en) * 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
US20090048214A1 (en) * 2006-11-15 2009-02-19 Rigel Pharmaceuticals, Inc Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds
WO2009003136A1 (en) * 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
WO2009029682A1 (en) * 2007-08-28 2009-03-05 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
TR201807879T4 (tr) * 2007-11-07 2018-06-21 Rigel Pharmaceuticals Inc Bir su ayırma maddesi kullanılarak ıslak granülasyon.
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
DK2305300T3 (en) 2008-07-10 2016-06-06 Toray Industries Pharmaceutical composition for treatment and prevention of cancer
JP5603881B2 (ja) * 2009-01-15 2014-10-08 ライジェル ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼｃ阻害剤とその使用
US8389515B2 (en) * 2009-11-20 2013-03-05 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and prodrugs and their uses
US8618095B2 (en) 2010-04-13 2013-12-31 Rigel Pharmaceuticals, Inc. 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
MX2012013274A (es) 2010-05-21 2013-05-28 Chemilia Ab Novedosos derivados de la pirimidina.
JP5744021B2 (ja) 2010-06-30 2015-07-01 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
JP5886411B2 (ja) 2011-03-24 2016-03-16 ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ 新規のピリミジン誘導体
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
MX339685B (es) 2011-07-28 2016-06-06 Rigel Pharmaceuticals Inc Formulaciones de (trimetoxifenilamino) pirimidinilo nuevas.
ES2661444T3 (es) 2011-12-28 2018-04-02 Fujifilm Corporation Nuevo derivado de nicotinamida o sal del mismo
US20130310387A1 (en) 2012-05-16 2013-11-21 Novartis Ag Monocyclic Heteroaryl Cycloalkyldiamine Derivatives
WO2013189241A1 (zh) * 2012-06-20 2013-12-27 上海恒瑞医药有限公司 嘧啶二胺类衍生物、其制备方法及其在医药上的应用
CN103804382A (zh) * 2012-11-05 2014-05-21 韩文毅 一类治疗湿疹的化合物及其用途
CN103102412B (zh) * 2013-01-29 2014-03-26 陈仁杰 人源抗鼻咽癌LMP2A胞外区抗体Fab及其应用
AU2016209737A1 (en) * 2015-01-23 2017-08-17 Erasmus University Medical Center Rotterdam Anti-senescence compounds and uses thereof
CN108025013A (zh) * 2015-08-12 2018-05-11 博尔托拉制药公司 用于治疗骨髓瘤的赛度替尼
IL288519B2 (en) 2015-11-02 2023-09-01 Blueprint Medicines Corp inhibitors of ret
RU2621187C1 (ru) * 2016-05-13 2017-06-01 Общество с ограниченной ответственностью "Молекулярные Технологии" Новая кристаллическая солевая форма 2,2-диметил-6-((4-((3,4,5-триметоксифенил)амино)-1,3,5-триазин-2-ил)амино)-2н-пиридо[3,2-в][1,4]оксазин-3(4н)-она для медицинского применения
AU2017325844A1 (en) 2016-09-14 2019-03-07 Gilead Sciences, Inc. SYK inhibitors
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
WO2018195471A1 (en) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Syk inhibitors in combination with hypomethylating agents
HRP20240124T1 (hr) 2018-04-03 2024-04-12 Blueprint Medicines Corporation Inhibitori za ret za uporabu u liječenju raka koji ima ret alteraciju
US12448366B2 (en) 2020-05-29 2025-10-21 Rigel Pharmaceuticals, Inc. Solid forms of pralsetinib
JPWO2023182460A1 (cg-RX-API-DMAC7.html) * 2022-03-24 2023-09-28
WO2024037910A1 (en) * 2022-08-17 2024-02-22 Institut National de la Santé et de la Recherche Médicale Syk inhibitors for use in the treatment of cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
ATE261730T1 (de) * 1997-12-31 2004-04-15 Univ Kansas Wasserlösliche medikamentenvorstufen tertiärer amine enthaltender medikamente und verfahren zu ihrer herstellung
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
CN1307173C (zh) 2000-12-21 2007-03-28 葛兰素集团有限公司 作为血管生成调节剂的嘧啶胺
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003026664A1 (en) 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
WO2003040141A1 (en) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
WO2003055489A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
MXPA04008999A (es) * 2002-03-20 2004-12-07 Squibb Bristol Myers Co Profarmacos de fosfato de fluorooxindoles.
ES2445208T3 (es) 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
WO2004014832A2 (en) 2002-08-02 2004-02-19 Vanetta S.P.A. Redox process particularly for the production of menadione and use of polyoxometalates
WO2004087698A2 (en) 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
PT1656372E (pt) * 2003-07-30 2013-06-27 Rigel Pharmaceuticals Inc Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina
DK1663242T3 (da) 2003-08-07 2011-08-01 Rigel Pharmaceuticals Inc 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
WO2005027848A2 (en) 2003-09-19 2005-03-31 Barnes-Jewish Hospital Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators
US20050267182A1 (en) * 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
JP5095409B2 (ja) 2004-11-24 2012-12-12 ライジェル ファーマシューティカルズ， インコーポレイテッド スピロ２，４−ピリミジンジアミン化合物およびその使用
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
US20090048214A1 (en) 2006-11-15 2009-02-19 Rigel Pharmaceuticals, Inc Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds

Also Published As

Publication number Publication date
JP5204761B2 (ja) 2013-06-05
CA2649549C (en) 2011-10-18
JP2009534397A (ja) 2009-09-24
US8227455B2 (en) 2012-07-24
EP2010181B1 (en) 2011-02-23
CA2649549A1 (en) 2007-11-01
DK2010181T3 (da) 2011-06-14
SI2010181T1 (sl) 2011-06-30
US8481521B2 (en) 2013-07-09
ATE499102T1 (de) 2011-03-15
ES2364657T3 (es) 2011-09-08
EP2010181A1 (en) 2009-01-07
WO2007124221A1 (en) 2007-11-01
US20120245127A1 (en) 2012-09-27
US20060276459A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
DE602007012677D1 (de) Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen
EA201490814A1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
EA201590230A1 (ru) Соединения пиразолопиримидина в качестве ингибиторов киназ
IL173722A0 (en) Proteasome inhibitors and methods of using the same
IL178675A0 (en) Monocyclic heterocycles as kinase inhibitors
EA201401062A1 (ru) Бициклические пиразиноновые производные
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
EA201890730A1 (ru) Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
IL184678A0 (en) Proteasome inhibitors and methods of using the same
PH12015500181A1 (en) Atx modulating agents
DK1664026T3 (da) Inhibitorer af mitotisk kinesin
ATE470439T1 (de) Verwendung von hif 1alfa modulatoren zur behandlung von krebs
EA201401212A1 (ru) Производные пирролотриазинона
MX2012010212A (es) Terapias inhibidoras de autofagia basadas en tioxantona para tratar el cancer.
EA201791946A1 (ru) Лечение хронической реакции "трансплантат против хозяина" с применением ингибиторов syk
MX2018014577A (es) Combinacion de anticuerpo anti-cd20, inhibidor selectivo de quinasa p13-delta, e inhibidor de btk para tratar trastornos proliferativos de celulas b.
WO2013112651A3 (en) Proteasome activity modulating compounds
SG10201810575WA (en) Treatment of prostate cancer with tor kinase inhibitors
MY162518A (en) Proteasome inhibitors and methods of using the same
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors
ATE426605T1 (de) Inhibitoren von mitotischem kinesin
ATE482218T1 (de) Inhibitoren von mitotischem kinesin
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors